Objective.-To provide evidence-based treatment recommendations for adults with acute migraine who require treatment with injectable medication in an emergency department (ED). We addressed two clinically relevant questions: (1) Which injectable medications should be considered first-line treatment for adults who present to an ED with acute migraine? (2) Do parenteral corticosteroids prevent recurrence of migraine in adults discharged from an ED?
INTRODUCTION
Background and Justification.-Acute migraine causes 1.2 million visits to US emergency departments (ED) annually. 1 More than 20 different parenteral medications and combinations of medications are used to treat migraine in US EDs, including migraine-specific medications such as sumatriptan and dihydroergotamine (DHE), anti-dopaminergics, such as metoclopramide and the neuroleptic prochlorperazine, opioids, corticosteroids, nonsteroidal anti-inflammatory drugs, and anti-histamines such as diphenhydramine and promethazine. 1, 2 The causes of this heterogeneity in emergency practice have not been explored systematically but are probably multifactorial and include physician comfort and familiarity with specific medications, concern about short-term side effects, beliefs about efficacy, and response to patient request. The ideal parenteral medication would offer rapid and sustained headache freedom, without short or long-term sequelae, and allow patients to return rapidly to work or usual daily activities. Unfortunately, such a medication does not exist. Published clinical trials demonstrate that fewer than 25% of patients experienced sustained headache freedom after treatment of acute migraine in the ED. 3 Many of the medication classes listed above have been associated with irreversible but uncommon side effects such as ischemic vascular complications with migraine-specific medications, tardive dyskinesia with anti-dopaminergics, avascular osteonecrosis with corticosteroids, gastrointestinal hemorrhage with NSAIDs, and medication dependence with opioids. ED-based clinical trials have only rarely followed patients for a sufficiently long period of time. Few of these studies had adequate power to detect these uncommon downstream sequelae. Given the very large number of migraineurs presenting to US EDs annually, the heterogeneity in current emergency practice, and the frequent use of potentially harmful medications, it is important to know which parenteral medications should be considered first-line therapy.
Clinical Question Statement.-The purpose of this guideline is to provide an evidence-based answer to each of the following questions.
1. Which injectable medications should be considered first-line treatment for adults who present to an ED with acute migraine? 2. Do parenteral corticosteroids prevent recurrence of migraine in adults discharged from an ED?
METHODS
Authorship Committee.-The American Headache Society (AHS) Guideline Committee determined the need for a guideline statement on this topic and assembled a panel of AHS members with the expertise required to develop this guideline. As per AHS's policy, the authorship committee adhered to the American Academy of Neurology's Clinical Practice Guideline Process Manual 4 with regard to searching, abstracting, synthesizing, and grading the quality of the evidence, as well as using the available evidence to construct a guideline statement. The AHS provided a meeting room for the participants during its 57th annual national meeting in Washington, DC (June 18th, 2015) . No other material support was provided. No outside funding was used throughout this guideline development. The AHS's guidelines committee and executive board approved this statement. Search Strategy.-In consultation with a medical research librarian, we developed a comprehensive search strategy to ensure that all relevant evidence was considered. For the first question, we aimed to identify all randomized studies of adults with acute migraine in which an injectable therapeutic was compared to placebo or to an active control. Studies were included only if the headache met International Classification of Headache Disorder migraine criteria. 5 Acceptable routes of drug delivery included intravenous, intramuscular, and subcutaneous injections. To qualify for inclusion, the study needed to measure acute outcomes, defined as assessment within 6 hours of medication administration. For the second question, we aimed to identify all randomized studies of adults with acute migraine in which a corticosteroid medication was compared to placebo. Again, studies were included only if the headache met International Classification of Headache Disorder migraine criteria. 5 To qualify for inclusion, the study needed to measure subacute outcomes, defined as an assessment within 1 week of ED discharge. For both questions, we searched for published studies in the Medline, Embase, and Cochrane Central Register of Controlled Trials databases and looked for additional unpublished studies using two registries: http:// clinicaltrials.gov and the WHO International Clinical Trial Registry Platform. In addition, we searched references of included studies. Our search strategy is presented in more detail in Figure S1 .
Study Selection.-We used a two-step process to select studies. Two authors (S.L.O., S.C.) reviewed all abstracts identified in the search. Many of these abstracts were rejected out of hand as not relevant. At least two authors (S.L.O., B.W.F., S.C.) performed a more detailed review of studies deemed potentially eligible. Disagreements about whether or not the study met selection criteria were resolved through discussions among three members (S.L.O., B.W.F., S.C.) of the panel.
Data Abstraction.-Data abstraction was performed by one author and verified by a second (S.L.O., B.W.F., S.C.). We developed a Characteristics of Study worksheet, which was used for each included study. On this worksheet, we recorded information about the study characteristics, setting, participants, interventions, and outcomes.
Classifying the Evidence-Risk of Bias.-We used the American Academy of Neurology's risk of bias tool to grade study quality (Appendix 1). 4 With this instrument, randomized studies receive the highest score if they provided a clear description of eligibility criteria, assessed outcomes in a masked and objective manner, concealed allocation, used no more than two primary outcomes, accounted for discrepancies in baseline characteristics, and if at least 80% of randomized patients were available for data analysis. Crossover studies were required additionally to have a sufficient washout period, no period effect, and to have used appropriate statistics. Using this instrument, the highest quality RCTs received a class 1 grade, and the lowest quality RCTs received a class 3 grade. Nonrandomized studies were not considered as primary evidence in this review. At least two authors (S.L.O., B.W.F., S.C.) graded each study. Discrepancies were resolved through discussion and, if needed, a third panel member was consulted to break the tie. Synthesizing the Evidence (Formulating Evidence-Based Conclusions).-For each acute migraine therapeutic, we considered the quality of the available evidence and the magnitude, precision, and consistency of results. Studies conducted in an ED were prioritized over studies conducted in the clinic or outpatient setting. Meta-analysis was performed when there were both a sufficient number of homogeneous studies and uncertainty with regard to the direction, magnitude, or precision of results. Sufficient homogeneity required at least two studies to have used the same medication, the same comparator, and the same outcome. The Cochrane Collaborations' Review Manager 5.3.5 software (RevMan: http://tech.cochrane.org/revman) was used to perform the meta-analysis. An assessment of statistical heterogeneity was performed using the chi square test, in which the threshold for considering a body of evidence heterogeneous was set at P .1, and the I-squared test, where the threshold was set at 30%. This result, combined with an assessment of clinical heterogeneity, was used to determine whether to use a fixed or random effects model. Event rates and sample sizes were entered into the RevMan software and the appropriate Mantel-Haenszel model (fixed or random effects) was selected to compute odds ratios and 95% confidence intervals.
For each medication, we came to a conclusion about certainty of efficacy. Multiple class 1 studies with a consistent conclusion led to a highly likely to be effective (or ineffective) conclusion. One class 1 study or multiple class 2 studies resulted in a likely to be effective (or ineffective) conclusion. Multiple class 3 or one class 2 study resulted in a possibly effective (or ineffective) conclusion. Lower levels of evidence or conflicting evidence resulted in the following conclusion: there is insufficient evidence to support or refute efficacy.
Developing Recommendations.-We attempted to create a recommendation for every medication included in the studies identified in our search. We also attempted to create a recommendation for every medication used in more than 5% of US ED migraine visits. To determine whether a medication was used in more than 5% of US ED migraine visits, we relied on the National Hospital Ambulatory Medical Care survey, a publically available probabilistic sample published by the National Center for Health Statistics. 6 Recommendations were based largely on conclusions about the certainty of efficacy (Appendix 2). We weighed certainty of efficacy against frequency and severity of adverse medication effects. Absent clear evidence of efficacy (or lack of efficacy), we considered inferences from widely accepted principles about medication effects on pain or the central nervous system. We contextualized rare, but potentially lifealtering, adverse medication effects using published literature.
RESULTS
Our search identified 2050 studies of which 68 were included in the review (PRISMA flow diagram, Fig. 1 ). These 68 studies included 28 different injectable medications. Of the 68 studies, 19 were rated class 1 (low risk of bias), 21 were rated class 2 (higher risk of bias), and 28 were rated class 3 (highest risk of bias). Our search for question #2 did not reveal any eligible studies that did not appear in the search for question #1 because all eligible corticosteroid RCTs utilized injectable medication.
Which Injectable Medications Should Be Considered First-Line Treatment for Adults Who Present to an ED With Acute Migraine?-Acetaminophen.-We identified three studies of IV acetaminophen (Table S1 ). [7] [8] [9] In one class 1 study, in which 60 patients were randomized to acetaminophen 1000 mg or placebo, a comparable number of patients were pain free at 2 hours. 8 In the acetaminophen arm, 4/30 (13%) patients had minor adverse events. In a class 2 study, in which 200 patients were randomized to acetaminophen 1000 mg or dexketoprofen 50 mg, pain scores were comparable 15 and 30 minutes after medication administration. 9 There were no adverse events in either group. In a class 3 study of 148 patients, propacetamol 1000 mg, a prodrug of acetaminophen, outperformed rizatriptan 5 mg PO at 60 minutes, though not at 30 or 120 minutes. 7 In this study, adverse events were not reported. Acetylsalicylic Acid.-We identified four randomized studies of intravenous acetylsalicylic acid. [10] [11] [12] [13] A class 2 study randomized 275 adults to 1 gm acetylsalicylic acid, sumatriptan 6 mg SC or placebo.
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Sumatriptan and acetylsalicylic acid both outperformed placebo. Sumatriptan also outperformed acetylsalicylic acid. However, the latter was tolerated as well as placebo, with significantly fewer adverse events than sumatriptan.
A class 2 study randomized 40 adults to 1 gm of lysine acetylsalicylic acid or 800 mg of valproic acid. 11 Pain relief at 1 hour and sustained pain freedom for 24 hours were comparable between the groups. No adverse events were reported in either arm. Another class 2 study randomized 40 patients to 500 mg of acetylsalicylic acid or placebo. 13 The active arm demonstrated greater pain relief on a visual analog scale (VAS). No adverse events were reported in either group. In a class 3 study, 56 patients were randomized to 1 gm acetylsalicylic acid or 0.5 mg ergotamine SC. 12 Substantially more patients in the acetylsalicylic arm achieved the primary outcome. These acetylsalicylic acid patients also tolerated the medication better than those given ergotamine. Chlorpromazine.-We identified three randomized studies of parenteral chlorpromazine.
14-16 A class 2 study randomized 60 adults to chlorpromazine 0.1 mg/kg or placebo. 14 The chlorpromazine group reported greater improvements in pain at 30 and 60 minutes than placebo, though patients in the active group reported more adverse events, most commonly orthostatic hypotension and drowsiness. In a class 3 study, 91 patients were randomized to chlorpromazine 0.1 mg/kg or metoclopramide 0.1 mg/kg. 15 Efficacy and adverse events were comparable between the groups. In another class 3 study, 30 patients were randomized to chlorpromazine 25 mg IV or ketorolac 60 mg IM. 16 At 2 hours, there was no difference between the groups in pain outcomes. No adverse events were reported in either group. Dexamethasone.-We identified four randomized studies in which dexamethasone was compared to an active comparator or placebo and acute outcomes were ascertained. [17] [18] [19] [20] In a class 1 study, 205 patients were treated with metoclopramide and diphenhydramine. 18 Patients were then randomized to dexamethasone 10 mg IV or placebo. There was no difference between the groups in the proportion of patients achieving pain freedom at 2 hours or in the frequency of adverse events, though more patients in the dexamethasone arm developed localized pain reactions.
In a class 2 study, 190 patients were randomized to dexamethasone 8 mg IV or morphine 0.1 mg/kg IV. 20 Patients randomized to morphine reported lower pain scores at 1 hour, though the between-group difference was less than standard thresholds for clinical significance. 21 Adverse events
were not reported in this study. In a class 3 study, 31 patients were randomized to dexamethasone 16 mg IV or valproic acid 900 mg IV. 17 In this study, there were no differences between the groups in improvement in pain score.
No adverse events were reported in this study. In another class 3 study, 90 patients were randomized to dexamethasone 0.15 mg/kg IV or propofol 10 mg IV, dosed every 5-10 minutes up to 80 mg. 19 Patients in the propofol group reported greater decreases in pain intensity at all time points up to 45 minutes. Patients in the propofol group were very likely to report sedation. Oxygen desaturations occurred in two patients who received propofol. Dexketoprofen.-We identified two randomized studies of dexketoprofen. 9, 22 In a class 1 study, 224
adults were randomized to dexketoprofen 50 mg IV or placebo. 22 The active group had substantially greater improvement in pain intensity at 30 and 45 minutes. No adverse events were reported. In a class 2 study, 200 adults were randomized to dexketoprofen 50 mg or acetaminophen 1 gm. Fifteen and 30 minutes after medication administration, there were no differences in pain scores. No adverse events were reported in either group. Diclofenac.-We identified three randomized studies of diclofenac. [23] [24] [25] A class 3 study randomized 120 patients to diclofenac 75 mg IM or placebo. 23 At 1 hour, the diclofenac patients had greater rates of headache relief than placebo. Adverse events were not reported. Another class 3 study randomized 47 patients to diclofenac 75 mg IM or tramadol 100 mg IM. 24 There were no between-group differences in any outcomes. Adverse events were uncommon.
A third class 3 study randomized 34 adults to diclofenac 75 mg IM or DHE 1 mg IM. 25 All patients received metoclopramide 10 mg IV. Outcomes at 1 and 2 hours were mixed. Adverse events were not reported.
Dihydroergotamine.-We identified two randomized studies of DHE. 25, 26 In a class 3 study, 310
patients were randomized to DHE 1 mg SC or sumatriptan 6 mg SC. Outcomes favored sumatriptan at 1 and 2 hours though not at 3 hours. There were 305 adverse events reported among the 152 patients who received DHE and 238 adverse events among the 158 patients who received sumatriptan. In another class 3 study, 34 adults were randomized to DHE 1 mg IM or diclofenac 75 mg IM. All patients received metoclopramide 10 mg IV. Outcomes at 1 and 2 hours were mixed. Adverse events were not reported. Diphenhydramine.-We identified one study of diphenhydramine for migraine. 27 In a class 1 study, there were no differences in outcomes or adverse events among 208 adults randomized to diphenhydramine 50 mg IV or placebo. All patients received metoclopramide 10 mg IV. A discussion of the efficacy of diphenhydramine to prevent extrapyramidal symptoms is beyond the scope of this review. However, in this class 1 study, in which all patients were administered IV metoclopramide, there was no difference in the rate of extrapyramidal symptoms between those who received diphenhydramine and those who did not.
Dipyrone.-We identified two randomized studies of dipyrone for migraine. 28, 29 In a class 2 study, 134
adults were randomized to intravenous dipyrone 1 gm or placebo. 29 The active arm had greater headache relief at 30 and 60 minutes. There was no difference in the overall rate of adverse events. In another class 2 study, 27 adults were randomized to dipyrone or metoclopramide. 28 There was no difference in pain intensity at 2 hours. No significant adverse events were reported. Droperidol.-We identified two randomized studies of droperidol. 30, 31 In a class 2 study, 305 patients were randomized to placebo or to doses of IM droperidol ranging from 0.1 to 8.25 mg. 30 Doses of droperidol from 2.75 to 8.25 mg outperformed placebo with regard to headache response at 2 hours. Adverse events were greater among those who received the active medication. In a class 3 study, 29 adults were randomized to droperidol 2.5 mg IM or meperidine 1.5 mg/kg IM. 31 There were no between group differences in efficacy. Akathisia occurred in 13% of those who received droperidol. Sedation occurred in 7% of the droperidol arm.
Ergotamine.-We identified one class 3 study of ergotamine, in which ergotamine 0.5 mg SC was compared with 1 gm of IV acetylsalicylic acid.
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More patients in the acetylsalicylic acid group achieved a 50% pain reduction while more patients in the ergotamine group reported nausea and vomiting.
Haloperidol.-We identified two randomized studies of haloperidol. 32, 33 In a class 1 study, 64 patients were randomized to haloperidol 5 mg IV or metoclopramide 10 mg IV. 32 All patients also received diphenhydramine 25 mg IV. There were no statistically significant differences in change in pain intensity, the primary outcome, though use of rescue medication was less common in the haloperidol group. Side effects were comparable between the two arms. In a class 3 study, 40 adults were randomized to haloperidol 5 mg IV or placebo. 33 Substantially more participants in the haloperidol group reported marked relief, though 80% of the haloperidol group reported side effects including 53% with motor agitation.
Ketamine.-We identified one class 3 crossover study of ketamine in which 17 adults were randomized to ketamine 0.08 mg/kg or placebo. 34 Patients who received ketamine reported significantly larger decreases in pain intensity, though feelings of fatigue or insobriety were common. Ketorolac.-We identified four randomized studies of ketorolac. 16, [35] [36] [37] In a class 1 study, 330 patients were randomized to ketorolac 30 mg IV, metoclopramide 10 mg IV, or valproate 1 gm IV. 36 Ketorolac and metoclopramide demonstrated similar rates of headache relief at 1 and 48 hour sustained relief, and both were superior to valproic acid. Overall adverse event rates were comparable. In a class 3 study, 47 patients during 50 ED visits were randomized to ketorolac 60 mg IM or meperidine 100 mg 1 hydroxyzine 50 mg IM. 35 There were no significant differences between the groups with regard to efficacy or adverse events.
A second class 3 study randomized 31 patients to ketorolac 30 mg IM or meperidine 75 mg IM. 37 The ketorolac group experienced significantly less pain reduction at 1 hour than the meperidine group. Adverse events were comparable.
In a third class 3 study, 30 patients were randomized to ketorolac 60 mg IM or chlorpromazine 25 mg IV. 16 Results at 2 hours were comparable. Adverse events were not reported.
Lidocaine.-In a class 2 study, 25 patients were randomized to lidocaine 1 mg/kg or normal saline. 38 There were no differences in efficacy between groups. No adverse events were reported. Lysine Clonixinate.-In a class 3 study, 29 patients were randomized to IV lysine clonixinate or placebo. 39 Lysine clonixinate had higher rates of headache freedom at 60 and 90 minutes, though adverse events were more common in this group as well. Magnesium.-We identified five randomized studies of magnesium. [40] [41] [42] [43] [44] In a class 1 study, 44 patients were randomized to magnesium 2 gm IV or placebo. 42 All patients also received metoclopramide 20 mg IV. There was no statistically significant difference in the primary outcome, which was improvement on a VAS between baseline and ED discharge, though more patients randomized to placebo improved by 50% on the VAS and more placebo patients reported normal functionality at the time of ED discharge. Adverse events were more common in the magnesium arm. In a class 2 study, 70 patients were randomized to magnesium 1 gm IV or dexamethasone 8 mg 1 metoclopramide 10 mg IV. 44 Patients randomized to magnesium reported greater decreases in pain intensity at 20 minutes, 1 hour, and 2 hours as compared to dexamethasone 1 metoclopramide. There was no difference in the frequency of adverse events. In another class 2 study, 60 patients were randomized to magnesium 1 gm or placebo. 40 Magnesium demonstrated greater headache relief and headache freedom at 30 and 60 minutes among those patients with migraine with aura, though not among those without aura. Adverse events were not reported. In a class 3 study, 30 patients were randomized to magnesium 2 gm IV or placebo. 43 Nearly every magnesium patient reported improvement vs none in the placebo group. Flushing was more common among those who received magnesium. In another class 3 study, 113 patients were randomized to magnesium 2 gm IV, metoclopramide 10 mg IV, or placebo. 41 There were no statistically significant differences between groups with regard to pain intensity at 30 minutes. Flushing was more common in the magnesium group. Meperidine.-We identified three randomized studies of meperidine. 31, 35, 37 In a class 3 study, 47
patients (during 50 visits) were randomized to meperidine 100 mg 1 hydroxyzine 50 mg IM or ketorolac 60 mg IM. 35 There were no significant differences between groups in the frequency of headache relief or side effects. In another class 3 study, 31 adults were randomized to meperidine 75 mg IM or ketorolac 30 mg IM. 37 Those randomized to meperidine reported greater pain relief. Adverse events were comparable. In a class 3 study, 29 patients were randomized to meperidine 1.5 mg/kg IM or droperidol 2.5 mg IM. 31 Efficacy results were comparable as was drowsiness.
Metoclopramide.-We identified 8 randomized studies of metoclopramide. 15, 28, 32, 36, 41, [45] [46] [47] In a class 1 study, 64 patients were randomized to metoclopramide 10 mg IV or haloperidol 5 mg IV. 32 All patients were also treated with diphenhydramine 25 mg IV. There was no statistically significant difference in pain relief at 80 minutes. Patients in the haloperidol arm required rescue medication less frequently. The frequency of adverse events was comparable.
In another class 1 study, 330 patients were randomized to metoclopramide 10 mg IV, ketorolac 30 mg IV, or valproate 1 gm IV. 36 Metoclopramide and ketorolac demonstrated similar rates of headache relief at 1 and 48 hour sustained relief, and both were superior to valproic acid. Overall adverse event rates were comparable. In a third class 1 study, 77 adults were randomized to metoclopramide 20 mg IV or prochlorperazine 10 mg IV. 47 All patients received diphenhydramine 25 mg IV. There was no difference between the groups in improvement in pain intensity at 1 hour. Adverse event rates were comparable between the groups. In the fourth class 1 study, 78 patients were randomized to metoclopramide, which was dosed in successive 20 mg doses up to 80 mg, as needed for persistent pain, or to sumatriptan 6 mg SC. 45 Patients who received metoclopramide were also treated with IV diphenhydramine. There was no difference between the groups in reduction in pain intensity, though secondary outcomes including pain freedom at 2 hours and requirement of rescue medication favored metoclopramide. Adverse events were comparable. In a class 2 study, 27 adults were randomized to metoclopramide or dipyrone. 28 There were no differences in pain intensity at 2 hours. No significant adverse events were reported. In a class 3 study, 91 patients were randomized to metoclopramide 0.1 mg/kg or chlorpromazine 0.1 mg/kg. 15 Efficacy and adverse events were comparable between the groups. In a class 3 study, 113 patients were randomized to metoclopramide 10 mg IV, magnesium 2 gm IV, or placebo. 41 There were no statistically significant differences between groups with regard to pain intensity at 30 minutes. Flushing was more common in the magnesium group. In a class 3 study, 124 patients were randomized to metoclopramide 20 mg IV or sumatriptan 6 mg SC. 46 The metoclopramide group demonstrated greater reduction in pain at 1 hour. Adverse events were not reported.
Morphine.-In a class 2 study, 190 patients were randomized to morphine 0.1 mg/kg IV or dexamethasone 8 mg IV. 20 Patients randomized to morphine reported lower pain scores at 1 hour, though the between-group difference was less than standard thresholds for clinical significance. 21 Adverse events were not reported in this study.
Octreotide.-We identified 3 randomized studies of octreotide. [48] [49] [50] In a class 1 crossover study, 43
patients were randomized to octreotide 0.1 mg SC or placebo. 49 There was no difference between the groups with regard to headache relief at 2 hours. Adverse events were comparable. In a class 2 study, 29 patients were randomized to octreotide 0.1 mg SC or placebo. 48 The octreotide group had greater reduction in pain at 2 and 6 hours. Local reactions were more common in the octreotide group. In another class 2 study, 44 patients were randomized to octreotide 0.1 mg IV or prochlorperazine 10 mg IV. 50 Prochlorperazine was superior with regard to patient satisfaction and reduction in pain intensity. Sedation and akathisia were more common with prochlorperazine.
Prochlorperazine.-We identified four randomized studies of prochlorperazine. 47, [50] [51] [52] In a class 1 study, 66 patients were randomized to prochlorperazine 10 mg 1 diphenhydramine 12.5 mg IV or sumatriptan 6 mg SC. 51 There was a significantly greater decrease in pain intensity at 80 minutes in the prochlorperazine group. Restlessness was more common in the prochlorperazine group. In a class 1 study, 77 adults were randomized to prochlorperazine 10 mg IV or metoclopramide 20 mg IV. 47 All patients received diphenhydramine 25 mg IV. There was no difference between the groups in change in pain intensity at 1 hour. Adverse event rates were comparable between the groups.
In a class 2 study, 44 patients were randomized to prochlorperazine 10 mg IV or octreotide 0.1 mg IV. 50 Prochlorperazine was superior with regard to patient satisfaction and reduction in pain intensity. Sedation and akathisia were more common with prochlorperazine. In a class 3 study, 40 patients were randomized to prochlorperazine 10 mg IV or valproic acid 500 mg IV. 52 The prochlorperazine patients had a significantly greater decrease in pain intensity at 60 minutes. In the prochlorperazine group, 10% of patients were treated for akathisia.
Propofol.-We identified two randomized studies of propofol. 19, 53 In a class 2 study, 90 patients were randomized to propofol IV or sumatriptan 6 mg SC. 53 The propofol was administered in 30-40 mg boluses with subsequent 10-20 mg boluses every 3-5 minutes up to 120 mg. At 30 minutes, there was a statistically significantly greater decrease in pain intensity in the propofol group. Chest tightness was less common in the propofol group. In a class 3 study, 90 patients were randomized to propofol 10 mg IV, dosed every 5-10 minutes up to 80 mg or dexamethasone 0.15 mg/kg IV. 19 Patients in the propofol group reported greater decreases in pain intensity at all time points up to 45 minutes. Patients in the propofol group were very likely to report sedation. Oxygen desaturation occurred in 2 patients who received propofol. Sumatriptan.-We identified 23 randomized trials of subcutaneous sumatriptan. 10, 26, 45, 46, 51, [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] Fifteen placebo controlled studies revealed large and consistent statistically significant differences between sumatriptan and placebo in four class 1 studies, 64 In a class 1 study, 66 patients were randomized to sumatriptan 6 mg SC or prochlorperazine 10 mg 1 diphenhydramine 12.5 mg IV. 51 There was a significantly greater decrease in pain intensity at 80 minutes in the prochlorperazine group. Restlessness was more common in the prochlorperazine group. In another class 1 study, 78 patients were randomized to sumatriptan 6 mg SC or metoclopramide, which was dosed in successive 20 mg doses up to 80 mg, as needed for persistent pain. 45 Patients who received metoclopramide were also treated with IV diphenhydramine. There was no difference between the groups in reduction in pain intensity, though secondary outcomes including pain freedom at 2 hours and requirement of rescue medication favored metoclopramide. Adverse events were comparable.
In a third class 1 study, 40 patients were randomized to sumatriptan 6 mg SC or trimethobenzamide 200 mg IM 1 diphenhydramine 25 mg IM. 59 Though there were no statistically significant differences between groups, the study was underpowered and most results favored sumatriptan. The overall rate of adverse events was comparable. A class 2 study randomized 275 adults to sumatriptan 6 mg SC, 1 gm acetylsalicylic acid, or placebo. 10 Sumatriptan and acetylsalicylic acid both outperformed placebo, while sumatriptan outperformed acetylsalicylic acid. However, the latter was tolerated as well as placebo, with significantly fewer adverse events than sumatriptan. In another class 2 study, 90 patients were randomized to sumatriptan 6 mg SC or propofol IV. 53 The propofol was administered in 30-40 mg boluses with subsequent 10-20 mg boluses every 3-5 minutes up to 120 mg. At 30 minutes, there was a greater decrease in pain intensity in the propofol group. Chest tightness was less common in the propofol group. A class 2 crossover study randomized 266 patients to sumatriptan 6 mg SC or to DHE 1 mg nasal spray. 69 The sumatriptan group had significantly better pain relief beginning at 15 minutes, though there were 50% fewer adverse events in the DHE group. In a class 3 study, 124 patients were randomized to sumatriptan 6 mg SC or metoclopramide 20 mg IV. 46 The metoclopramide group demonstrated greater reduction in pain at 1 hour. Adverse events were not reported. In another class 3 study, 310 patients were randomized to sumatriptan 6 mg SC or DHE 1 mg SC. 26 Outcomes favored sumatriptan at 1 and 2
hours though not at 3 hours. There were 305 adverse events reported among the 152 patients who received DHE and 238 adverse events among the 158 patients who received sumatriptan.
Tramadol.-A class 3 study randomized 47 patients to tramadol 100 mg IM or diclofenac 75 mg IM. 24 There were no between-group differences in any outcomes. Adverse events were uncommon.
Triamcinolone.-In a class 3 study of greater occipital nerve blocks, 37 patients were randomized to subcutaneous injections of lidocaine, bupivacaine, and 40 mg of triamcinolone or the two local anesthetics and saline. 71 Twenty minutes after the injection, there were no differences in pain scores between the groups. No adverse events were reported.
Trimethobenzamide.-In a class 1 study, 40 patients were randomized to trimethobenzamide 200 mg IM 1 diphenhydramine 25 mg IM or to sumatriptan 6 mg SC. 59 Although there were no statistically significant differences between groups, the study was underpowered and most results favored sumatriptan. In this study, there was no difference in the overall rate of adverse events. Valproic Acid.-We identified four randomized studies of valproic acid. 11, 17, 36 In a class 1 study, 330 patients were randomized to valproate 1 gm IV, ketorolac 30 mg IV, or metoclopramide 10 mg IV. 36 Ketorolac and metoclopramide demonstrated similar efficacy with regard to headache relief at 1 hour and sustained headache relief for 48 hours, and both were superior to valproic acid. Overall adverse event rates were comparable. A class 2 study randomized 40 adults to 1 gm of lysine acetylsalicylic acid or 800 mg of valproic acid. 11 Rates of pain relief at 1 and 24 hour sustained pain freedom were comparable between the groups. No adverse events were reported in either arm. In a class 3 study, 40 patients were randomized to valproic acid 500 mg IV or prochlorperazine 10 mg IV. 52 The prochlorperazine patients had a significantly greater decrease in pain intensity at 60 minutes. In the prochlorperazine group, 10% of patients were treated for akathisia. In another class 3 study, 31 patients were randomized to valproic acid 900 mg IV or dexamethasone 16 mg IV. 17 In this study, there was no difference between the groups in improvement in pain score. No adverse events were reported in this study.
Other Medications.-Hydromorphone, promethazine, and nalbuphine are each used in more than 5% of ED migraine visits annually. 1 However, these medications were not included in any clinical trials that fulfilled our selection criteria. Do Parenteral Corticosteroids Prevent Recurrence of Migraine in Adults Discharged from an ED?-We identified three eligible RCTs in which a corticosteroid was compared to placebo and post-ED outcomes were ascertained (Table S1) . 18, 72, 73 All three of these studies utilized dexamethasone. Two additional RCTs compared dexamethasone to active comparators. In one, dexamethasone was compared to morphine 0.1 mg/kg IV 20 ; in the other to valproic acid 900 mg IV. 17 In a class 1 study involving 115 patients, dexamethasone 24 mg IV did not outperform placebo with regard to migraine recurrence at 3 or 30 days. 72 In this study, dizziness was more common among those who received dexamethasone. In another class 1 study involving 205 patients, all patients received metoclopramide and diphenhydramine. 18 One hundred and six of these patients also received dexamethasone 10 mg IV. There were no between-group differences in the rates of sustained headache freedom 24 hours after ED discharge. Acute medication reactions were more common in the dexamethasone group. In a third class 1 study of 70 patients, dexamethasone 10 mg IV did not outperform placebo with regard to migraine recurrence within 48 hours of ED discharge. 73 Adverse events were not reported. We performed a meta-analysis in which we aggregated data from these three placebo controlled studies. These results are presented in Figure 2 . In the Friedman et al study, the primary outcome was sustained headache freedom. For the purpose of this meta-analysis, we used data provided by the authors on frequency of headache recurrence after ED discharge. When the data from these three studies were aggregated, dexamethasone decreased the frequency of headache recurrence after ED discharge (number needed to treat: 9, 95%CI: 5, 65). As can be seen in Figure 2 , there was no statistical heterogeneity among the studies. All three studies reported a small but consistent benefit attributable to dexamethasone. When aggregated, this result was statistically significant.
The comparison with morphine was a class 2 study, in which dexamethasone 8 mg IV demonstrated greater improvement in pain scores at 24 hours. 20 Adverse events were not reported. The comparison with valproic acid was a class 3 study, in which dexamethasone 16 mg IV resulted in comparable headache recurrence rates at 72 hours. 17 This study, too, did not report adverse events. There were no reports in these studies of avascular necrosis, a serious adverse event linked to corticosteroid use, infections, or complications relating to loss of glycemic control. However, none of these studies were designed to detect these adverse events.
LIMITATIONS
A multitude of different methodologies were used in the studies included in this review. While the inclusion criteria were generally similar, some studies used placebo control and some used active control, some were dose-finding studies, and some used multiple active comparators. Different time points were used for the primary outcome, and different outcomes were designated as being primary or secondary. We did not identify a single outcome that was used across all studies included in this review. Some of these studies, particularly those utilizing sumatriptan, were conducted outside of the ED setting. While these disparities do not mean that the studies included in this review were unduly biased, the disparities limited our ability to aggregate data and compare results across studies. A standardized methodology for ED-based migraine studies is needed.
Furthermore, most studies included in this review did not follow patients beyond the initial treatment period. Thus, recurrence of headache after ED discharge and late developing adverse events often went unrecorded. Long-term follow-up beyond 48-72 hours was even rarer among the included studies, thus limiting our ability to comment on these.
While many studies were adequately powered for their primary outcome, they were underpowered for rare adverse events such as tardive dyskinesia or avascular necrosis. This also limits our ability to contextualize these important adverse effects with regard to frequency and severity.
CONCLUSIONS
We have identified 68 RCTs that inform the choice of injectable medical treatment of adults presenting to the ED with migraine. Five of these trials also provided evidence pertaining to the use of corticosteroids for the prevention of migraine recurrence after ED discharge. Analysis of these 68 trials provided the basis for our recommendations, listed below.
RECOMMENDATIONS
Putting the Evidence Into a Clinical Context.-When asked, migraine patients report that they want medications that take their pain away quickly and completely, without side effects and without headache recurrence. 74 However, ED migraine patients are often satisfied with modest reductions in pain. 3 While the former goal is ideal, and should be the ultimate goal, the latter is a more likely outcome of ED treatment. It is impossible to expect that these recommendations will provide the correct therapeutic answer for every migraine patient during every ED visit. Other factors, most importantly a patient's previous experience with a particular medication, and risk of adverse events, should be considered. The following recommendations are most appropriate for a patient who has never received an injectable migraine therapeutic in the ED (Table 1) . Acute Management of Migraine. Must Offer (Level A).-None Should Offer (Level B).-To relieve the acute headache, intravenous metoclopramide should be offered to adults who present to an ED with acute migraine (Should offer-Level B). Patients should be warned about the possibility of unpleasant side effects including akathisia and drowsiness (Table  2) . Irreversible adverse events have never been reported after one dose of intravenous metoclopramide.
To relieve the acute headache, intravenous prochlorperazine should be offered to adults who present to an ED with acute migraine (Should offer-Level B). Patients should be warned about the possibility of unpleasant side effects including akathisia and drowsiness (Table 2) .
To relieve the acute headache, subcutaneous sumatriptan should be offered to adults who present to an ED with acute migraine (Should offer-Level B). In the ED, sumatriptan may be less efficacious than intravenous anti-dopaminergics. Sumatriptan is not appropriate for patients with contra-indications to this medication and should not be offered to those who have used ergotamine, DHE, or a triptan medication within the previous 24 hours. Unpleasant side effects have occurred in 50% of ED patients administered this medication (Table 2) , 54 though irreversible adverse events in patients with low cardiovascular risk are exceedingly uncommon. May Offer and May Avoid (Level C).
OFFER. Intravenous acetaminophen may be offered to adults who present to an ED with acute migraine (May offer-Level C).
Intravenous acetylsalicylic acid may be offered to adults who present to an ED with acute migraine (May offer-Level C).
Parenteral chlorpromazine may be offered to adults who present to an ED with acute migraine (May offer-Level C). Patients should be warned about the possibility of unpleasant side effects including orthostatic hypotension, drowsiness, and akathisia.
Intravenous dexketoprofen may be offered to adults who present to an ED with acute migraine (May offer-Level C).
Intravenous diclofenac may be offered to adults who present to an ED with acute migraine (May offer-Level C).
Intravenous dipyrone may be offered to adults who present to an ED with acute migraine (May offer-Level C), an exceedingly rare but life threatening adverse event associated with dipyrone, has resulted in elimination of this medication from the United States and other countries.
Parenteral droperidol may be offered to adults who present to an ED with acute migraine (May offer-Level C). Patients should be warned about the possibility of unpleasant side effects including drowsiness and akathisia, which may occur in 50% of patients. Life threatening cardiac dysrhythmias occur exceedingly rarely after administration of this medication.
Parenteral haloperidol may be offered to adults who present to an ED with acute migraine (May offer-Level C). Patients should be warned about the possibility of unpleasant side effects including drowsiness, and akathisia.
Intravenous ketorolac may be offered to adults who present to an ED with acute migraine (May offer-Level C).
Intravenous valproate may be offered to adults who present to an ED with acute migraine (May offer-Level C).
AVOID. Intravenous diphenhydramine may be AVOIDED in adults who present to an ED with acute migraine (May avoid-Level C). The efficacy of diphenhydramine with regard to treatment of akathisia was beyond the scope of this work. 
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Tramadol 100 mg IM This complication has rarely been reported after isolated doses of corticosteroids.
Loss of glycemic control may require medical management. criteria. As a first recommendation for future research, we support the development of a standard methodology for ED-based headache research. Patient priorities must be understood. Patient priorities can then be used to guide the development of standardized instruments and follow-up time points. While many patients are satisfied with the headache relief they obtain in the ED, 3 inadequate relief, adverse medication events, and recurrence of headache after ED discharge are very common. Using a standardized methodology, we hope that ED-based researchers continue to conduct and publish randomized trials of migraine therapeutics to optimize the injectable treatment that migraine patients receive in the ED. 
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